Aplastic Anemia

Navigating AI and Your Health: Opportunities, Risks and Practical Uses

Thumbnail for video Register Now

Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Related Bone Marrow Failure Diseases and Malignancies
AI is changing the way we find information, communicate, and manage our health. But how can patients use these tools effectively and safely? This webinar will introduce the basics of AI and demonstrate how patients can use safely use AI tools. We'll also discuss the risks of…

Second Transplantation for Relapsed Hematologic Malignancies After First Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-Matched Related Donor

Original Publication Date
Article Source
External Web Content

Highlights • Donor change at second allo-HCT did not improve survival after MRD-HCT relapse. • 23MM-RD was associated with inferior OS in the overall cohort. • Findings for 23MM-RD may not reflect contemporary PTCy-based transplantation. ABSTRACT Relapse after allogeneic…

Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation

Original Publication Date
Article Source
External Web Content
HIGHLIGHTS - Prophylactic rituximab reduces EBV infection and PTLD in high-risk allo-HCT recipients. - IPTW and Fine–Gray analyses confirm an independent reduction in EBV infection risk. - Despite delayed B-cell recovery, IgG levels and first-year IVIG use remain comparable…

Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence 

Original Publication Date
Article Source
External Web Content
Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a potentially curative therapy for various hematologic malignancies, bone marrow failure syndromes, and selected nonmalignant disorders. Advances in conditioning regimens, graft-versus-host disease (GVHD)…

Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation

Original Publication Date
Article Source
External Web Content
Highlights The analysis included 122 survivors who underwent HCT between 1972 and 2021 with a median interval between HCT and survey of 26.0 (range 1.1 to 47.1) yr. The most common reported chronic health conditions were problems with sexual desire, erection, ejaculation, vaginal…

Outcomes After Matched Sibling Donor Versus Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis 

Original Publication Date
Article Source
External Web Content
Highlights Haploidentical HSCT with post-transplant cyclophosphamide yields overall and disease-free survival rates statistically comparable to matched sibling donor transplants. Multivariable analysis confirms that GVHD-free/relapse-free survival (GRFS) outcomes are equivalent…

Finding the Right Path: Treatment Choices for Pediatric Aplastic Anemia

Thumbnail for video Register Now

Topic(s)
Pediatric Bone Marrow Failure Diseases
Presenter(s)
Timothy Olson, MD, PhD
In this webinar, Dr. Olson will explore treatment approaches for pediatric aplastic anemia, non-transplant therapies, and transplantation. Learn how treatment decisions are made, what factors influence the choice of treatment, and what families can expect throughout the treatment…
Subscribe to Aplastic Anemia

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.